Stocktoria
NEPHROS INC NEPH
NEPHROS INC (NEPH) earns a Piotroski F-score of 6/9 (mixed financial health). It does not currently pay a dividend. FY2025 revenue was $18.8M at a 6.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.46 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NEPH | NEPHROS INC | 6/9 | — | 32.8 | +32.7% |
| SNOA | Sonoma Pharmaceuticals, Inc. | 2/9 | — | — | +36.7% |
| MDAI | Spectral AI, Inc. | 3/9 | -11.78 | — | -33.6% |
| VVOS | Vivos Therapeutics, Inc. | 2/9 | — | — | +16% |
| PROF | Profound Medical Corp. | 5/9 | -3.44 | — | +50.7% |
| DRIO | DarioHealth Corp. | 3/9 | -12.4 | — | -17.3% |
| BDMD | Baird Medical Investment Holdings Ltd | 1/9 | 0.49 | — | -39.2% |
About NEPHROS INC
Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in foodservice and hospitality, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water; reduce biofilm and scale build-up; and remove cysts, particulates, and lead from water systems. It markets its products to food service and hospitality sectors including quick-service restaurants, convenience stores, and restaurants. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
FAQ
Is NEPH financially healthy?
NEPHROS INC's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak).
Does NEPH pay a dividend?
No, NEPHROS INC does not currently pay a dividend.
How profitable is NEPH?
In FY2025, NEPHROS INC had a net margin of 6.4% and a return on equity of 11.7%.
What is NEPH's P/E ratio?
NEPHROS INC's trailing price-to-earnings (P/E) ratio is about 32.8×, based on its latest annual earnings.
What is the analyst price target for NEPH?
The average Wall-Street price target for NEPHROS INC is $7.00, about 60.6% above the recent price, from 2 analysts.
Is NEPH a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on NEPHROS INC: a Piotroski F-score of 6/9, a P/E of about 32.8×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.